- Investing Ideas
- /
- Chinese Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Chinese Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
5
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
5 companies
Zhejiang Jolly PharmaceuticalLTD
Market Cap: CN¥11.7b
Engages in the research, production, and marketing of Chinese medicinal products in the People’s Republic of China and internationally.
300181
CN¥16.86
7D
-2.0%
1Y
2.2%
Shanghai OPM Biosciences
Market Cap: CN¥6.2b
Provides cell culture media and CDMO services in China and internationally.
688293
CN¥55.38
7D
-2.6%
1Y
28.9%
Beijing Aosaikang Pharmaceutical
Market Cap: CN¥15.3b
Beijing Aosaikang Pharmaceutical Co., Ltd.
002755
CN¥16.80
7D
-9.6%
1Y
27.0%
Suzhou Highfine Biotech
Market Cap: CN¥5.3b
Manufactures and sells chemicals for pharmaceutical research and development, and API production companies in China.
301393
CN¥50.86
7D
-7.2%
1Y
13.3%
Kexing Biopharm
Market Cap: CN¥6.4b
A biopharmaceutical company, engages in the research and development, production, and sale of recombinant protein drugs and microecological preparations in China, the European Union, Brazil, the Philippines, and Indonesia.
688136
CN¥33.33
7D
-3.6%
1Y
97.5%